A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease
A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease
The purpose of this study is to evaluate the effect of dapagliflozin on renal outcomes and cardiovascular mortality in patients with chronic kidney disease.
This is an international, multicentre, event-driven, randomized, double-blind, parallel group, placebo-controlled study, evaluating the effect of dapagliflozin versus placebo, given once daily in addition to standard of care, to prevent the progression of chronic kidney disease (CKD) or cardiovascular (CV)/renal death.
Inclusion Criteria:
Exclusion Criteria:
CABA, C1119ACN, Argentina
CABA, C1120AAC, Argentina
Ciudad Autonoma Buenos Aires, 1093, Argentina
Ciudad Autonoma de Buenos Aire, C1407GTN, Argentina
Maharashtra, 411013, India
Amagasaki-shi, 660-8550, Japan
Asahikawa-shi, 070-8644, Japan
Beppu-shi, 874-0011, Japan
Daito-shi, 574-0074, Japan
Fujisawa-shi, 251-8550, Japan
Higashiibaraki-gun, 311-3193, Japan
Iizuka-shi, 820-8505, Japan
Itabashi-ku, 173-8610, Japan
Kamakura-shi, 247-8533, Japan
Kawachinagano-shi, 586-8521, Japan
Kawasaki-shi, 211-8510, Japan
Koga-shi, 811-3195, Japan
Koshigaya-shi, 343-8577, Japan
Matsumoto-shi, 390-8621, Japan
Takarazuka-shi, 665-0861, Japan
Toride-shi, 302-0022, Japan
Tsuchiura-shi, 300-0028, Japan
Ueda-shi, 386-8610, Japan
Uji-shi, 611-0041, Japan
Yaizu-shi, 425-8505, Japan
D.F, 14000, Mexico
Deagu, 41944, South Korea
Chernivtsі, 58018, Ukraine
Kharkiv Region, 61039, Ukraine
Kharkiv Region, 61103, Ukraine
Kharkiv Region, 61166, Ukraine
Hochiminh, 700000, Vietnam